Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V2SP
|
|||
| Former ID |
DIB011014
|
|||
| Drug Name |
INGN-225
|
|||
| Synonyms |
Cancer vaccine (p53), Introgen
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42] | Phase 2 | [1] | |
| Company |
Introgen Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019096) | |||
| REF 2 | INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.